NON MUSCLE INVASIVE BLADDER CANCER

This study tests whether a virus-based treatment called cretostimogene grenadenorepvec can prevent intermediate-risk bladder cancer from returning after surgery. About 367 participants will either receive the treatment or be monitored. The goal is to see if the therapy extends th…

This study tests a new treatment called cretostimogene grenadenorepvec for people with a type of bladder cancer that did not get better with standard therapy. About 190 participants will receive this virus-based therapy to see if it can shrink tumors or delay cancer from coming b…

This study tests an experimental drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the safest dose and see if the drug can shrink tumors. About 310 adults whose cancer has not respon…

This study tests a new drug called sasanlimab (an immunotherapy) for people with early-stage bladder cancer that hasn't spread. In one part, patients with high-risk cancer receive sasanlimab plus standard BCG therapy, or BCG alone, to see if the combination better prevents the ca…

This study tests whether a combination of two chemotherapy drugs (Gemcitabine and Docetaxel) given directly into the bladder works as well as the standard BCG therapy for patients with high-grade non-muscle invasive bladder cancer who have not received BCG before. About 870 adult…

This study tests a combination of two drugs—BCG (a standard immunotherapy for bladder cancer) and durvalumab (an immune-boosting drug)—in adults with high-risk non-muscle-invasive bladder cancer who have not received BCG before. The goal is to see if the combination is safe and e…

This study tests a new drug called CG0070 in 20 people with intermediate-risk bladder cancer that hasn't spread into the muscle. After surgery to remove visible tumors, patients receive CG0070 to see if it is safe and helps prevent the cancer from coming back. The goal is to cont…

This study tests whether adding a new drug (N-803) to standard BCG therapy works better than BCG alone for people with a high-risk, early-stage bladder cancer. About 369 participants will receive either the combination or BCG alone. The goal is to see if the combo leads to more c…

This phase 3 study tests whether adding the immunotherapy drug durvalumab to standard BCG treatment helps people with high-risk non-muscle-invasive bladder cancer stay cancer-free longer. About 1,018 adults who have not had BCG before will be randomly assigned to receive either t…

This study looks at whether a urine test measuring SIX6 gene methylation can predict if low-risk bladder cancer will come back after surgery. Researchers will compare test results from 177 patients who had a recurrence versus those who did not. If accurate, this test could help d…

This study compares two treatments for a type of bladder cancer that keeps coming back: medication placed directly into the bladder versus surgery to remove the bladder. Researchers want to see which option gives patients a better quality of life and overall experience. About 570…

This study checks on the long-term health of 6 patients with non-muscle invasive bladder cancer who previously received an experimental treatment combining N-803 and BCG. Researchers will collect information on cancer status, survival, and any further treatments over several year…